AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04859114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
Study NCT04859114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
Study NCT06626620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate infusion
Description: Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
Study NCT06626620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline Infusion
Description: Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
Study NCT06627660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Valsalva maneuver
Description: Closure of the nose and mouth during expiration for 20 sec
Study NCT06627543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echo
Description: echocardiographic
Study NCT06725186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAX
Description: The RELAX intervention is a social-emotional intervention consisting of 8 weekly, 1.5 hr sessions and a booster session 1 month and 6 months after the completion of RELAX. During the first 60 minutes of RELAX sessions, parents and adolescents meet separately; during the last 30 minutes combined parent-adolescent discussion and problem-solving activities take place. RELAX is structured such that parents learn emotion regulation/coping skills the week prior to them being taught to the adolescents. Group sessions will involve both didactics and discussion of topics including psychoeducation, basic cognitive/behavioral principles, emotional awareness, emotion regulation strategies, parent emotion socialization practices, coping skills, conflict management strategies, and communication skills.
Study NCT06725186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Materials
Description: Infographics with information on emotion regulation development, emotion regulation strategies, and strategies for managing interpersonal conflict, including when different strategies are more or less effective will be provided to participants via email.
Study NCT04666961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Description: Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
Study NCT04666961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1Mg Tab
Description: Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
Study NCT05362162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical plexus block
Description: local anesthetic agent injection into the either Superficial or intermediate area
Study NCT05190575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
Study NCT06741423 — intervention group
Intervention type: OTHER
Intervention: Radiomics Algortihm
Description: A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.
Study NCT06742866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Injection
Description: Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.
Study NCT06742866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection 0.9%
Description: Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
Study NCT06743425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAMP Reports
Description: Participants will receive text-based requests for reports with embedded links to select radio button questionnaires directly on their mobile device. Questions include current inattention/hyperactivity symptoms, school performance, and any engagement in behavioral therapy. Inattention/hyperactivity symptom questions and scoring is taken directly from the publicly available Vanderbilt Rating Scales, which is a commonly used, guideline-recommended tool for both diagnosis and management of ADHD for use by parents and teachers.
Study NCT06743425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Education Handouts
Description: The digital education handouts will be sent via email to the control group and will serve as an attention control. They will consist of information regarding a general pediatric health topic and will be emailed at intervals matching the RAMP requests in the intervention group.
Study NCT06741826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
Description: Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
Study NCT06741618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyPEEPS Mobile
Description: An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence
Study NCT06741618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence
Study NCT06741618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic PrEP peer navigation
Description: Electronic peer navigation to PreP services
Study NCT06742177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Bi-level ESPB
Description: The block procedure is performed immediately before surgery begins after general anesthesia induction, with the patient in the lateral decubitus position. For the block, sterile conditions are provided with USG, and the erector spinae muscle and vertebral process are visualized, and the in plane technique is used. The target vertebral level for bi-level ESPB is two levels, T5 and T7. The block needle is advanced in the caudo-cranial direction, and the potential area between the erector spinae muscle and the transverse process of the relevant vertebra is targeted. The block location is confirmed by injecting 2 ml of saline between the transverse process and the muscle. After the block location is confirmed, a total of 40 ml of 0.25% bupivacaine is applied, using 20 ml of 0.25% bupivacaine for a single level.
Study NCT06742177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group M-TAPA block
Description: The procedure is performed in the supine position immediately before surgery after general anesthesia induction and the in plane technique is used. The transversus abdominis, internal oblique and external oblique muscles are identified at the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. The block needle is advanced in the caudo-cranial direction and a deep angle is given with the probe in the sagittal direction to the costochondral angle at the edge of the 10th rib to visualize the lower surface of the costal cartilage in the midline. The block location is confirmed by injecting 2 ml of saline onto the transverse abdominis muscle under the 10th costal cartilage. After the block location is confirmed, 20 ml of 0.25% bupivacaine is used. This procedure is repeated for the opposite side and a total of 40 ml of 0.25% bupivacaine is used.
Study NCT04888338 — intervention group
Intervention type: OTHER
Intervention: Data Capture
Description: Treatment related data is collected
Study NCT04888338 — intervention group
Intervention type: OTHER
Intervention: Electronic Medical Record
Description: Medical records are reviewed
Study NCT05068284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Intravenous (IV) Infusion; Subcutaneous Injection
Study NCT05068284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion; Subcutaneous Injection
Study NCT05068284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection
Study NCT05068284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT05796336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lip taping
Description: Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
Study NCT05068284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT06548958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Stem Cell Transplantation (SCT2)
Description: 1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg).
Study NCT05038904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg oral capsule
Study NCT04773600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream
Description: Roflumilast cream 0.15% for topical application
Study NCT04773600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream for topical application
Study NCT05315297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF device
Description: PEMF device wear overnight daily for four weeks
Study NCT05315297 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PEMF device
Description: Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
Study NCT04319822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample and muscular biopsy
Description: blood sample and muscular biopsy
Study NCT06531122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5MG
Description: 100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
Study NCT06531122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: 100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
Study NCT06686589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal ultrasound
Description: Intestinal ultrasound performed by hand held ultrasound devices
Study NCT05588063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
Study NCT05588063 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The device will appear to function but no electrical stimulation will be delivered.
Study NCT06072339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound for PEEP setting
Description: NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.
Study NCT06072339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation session
Description: The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above.
Study NCT06072339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation session
Description: The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above.
Study NCT06072339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood gas
Description: Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
Study NCT06072339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arterial blood gas
Description: Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
Study NCT06072339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview on pain and comfort
Description: The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
Study NCT06072339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview on pain and comfort
Description: The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
Study NCT06432985 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.
Study NCT06432985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM.
Study NCT06432985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling (Cognitive Behavioral Therapy, CBT)
Description: Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.
Study NCT06432985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Counseling (Cognitive Behavioral Therapy, CBT)
Description: Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.
Study NCT06432985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TUD Treatment as Usual (TAU)
Description: Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.
Study NCT06694896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microarray Application
Description: Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.
Study NCT06695741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
Study NCT05475938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Painting therapy and psychoanalysis
Description: Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
Study NCT04563520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPCC-emicizumab
Description: Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI.
Study NCT04563520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, routine prophylaxis to prevent or reduce the frequency of bleeding episodes. If there is less than a good' response in bleed event at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with a max dose of no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days.
Study NCT04563520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
Study NCT06501924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DA-005
Description: Oral Botanical Supplement HIF-1a inhibitor